FDA approves tesamorelin for HIV-related lipodystrophy
- New fenofibrate formulation offers more convenience. // Drug Topics;11/22/2004, Vol. 148 Issue 22, p6
Reports that the U.S. Food and Drug Administration has approved a formulation of fenofibrate tablets for the treatment of lipid disorders such as mixed dyslipidemia.
- FDA APPROVES MRSA DRUG. // Medical Economics;7/25/2014, Vol. 91 Issue 14, p7
The article reports the move by the U.S. Food and Drug Administration (FDA) as of July 2014 to approve the antibacterial drug Sivextro tedizolid phosphate for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI).
- Update: FDA Approves Crofelemer as First Oral Botanical Drug. Mader, Linday Stafford // HerbalGram;Feb-Apr2013, Issue 97, p68
The article reports on a 2012 announcement from the U.S. Food and Drug Administration. In the announcement the agency indicated that it had approved the orally administered botanical preparation of the substance crofelemer, which is derived from the latex of the South American sangre de drago...
- Metreleptin for injection: Orphan drug treats congenital or acquired generalized lipodystrophy. ALDRIDGE YOUNG, CARA // Pharmacy Today;April2014, Vol. 20 Issue 4, p41
The article discusses the drug approval made by the U.S. Food & Drug Administration (FDA) on the use for metreleptin for injection for treating complications of leptin deficiency in patients with congenital lipodystrophy. It mentions that FDA requires postmarketing studies for metreleptin...
- Biologies gaining ground against psoriasis. Jestius, John // Dermatology Times;May2005, Vol. 26 Issue 5, p32
The article reports that biologic drugs have proved to be effective in the treatment of psoriasis. The only biologic drug to be approved by the U.S. Food and Drug Administration (FDA) for treating psoriatic arthritis is Enbrel. This drug has been approved for the treatment of rheumatoid...
- Imiquimod approved for keratosis. // WHO Drug Information;2004, Vol. 18 Issue 3, p224
The article reports that the U.S. Food and Drug Administration (FDA) has approved imiquimod for the treatment of superficial basal cell carcinoma. The safety and effectiveness of imiquimod were established in two double-blind controlled studies of approximately 364 patients. Superficial basal...
- News from the FDA. Pennachio, Dorothy L. // Patient Care;Nov2003, Vol. 37 Issue 11, p11
Reports on the approval of several drugs by the U.S. Food and Drug Administration in November 2003. Wellbutrin XL for treating major depressive disorder in old patients; Paxil CR for treating pre-menstrual dysphoric disorder; Cubicin for treating skin structure infections; Zonegran for treating...
- News from the FDA. // Patient Care;Sep2005, Vol. 39 Issue 9, p4
Presents news briefs from the U.S. Food and Drug Administration as of September 2005. Indication received by Avelox for the treatment of complicated skin and skin structure infections in adults; Approval of Rozerem for the treatment of insomnia.
- Complicated infections. // Formulary;Apr2009, Vol. 44 Issue 4, p124
The article offers information on the new drugs approved by the U.S. Food and Drug Administration (FDA) that could cure complicated infections. Injectable ceplialosporin antibiotic for the treatment of complicated skin and skin-structured infections (cSSSis) caused by gram-positive and...